Oruka Therapeutics, Inc. ORKA Common stock, shares issued (in shares)

Common stock, shares issued (in shares) at other companies

AbbVieABBV

——

Arcutis Biotherapeutics, Inc.ARQT

——

ImmunityBio, Inc.IBRX

——

Immunovant, Inc.IMVT

——

Spyre Therapeutics, Inc.SYRE

——

Arcus BiosciencesRCUS

——

Other financials

Income statement

See full

Revenue-—

Operating income-$36.4M-45.2%

Net income-$31.8M-51.5%

EPS (diluted)-$0.46+93.4%

Balance sheet

See full

Cash & equivalents$49.5M-40.7%

Total debt$1.8M+90.8%

Total equity$486.7M+33.4%

Total assets$504.5M+33.8%

Cash flow

See full

Operating cash flow-$23.6M-13.0%

CapEx$73.0K+462%

Free cash flow-$23.7M-13.3%

Valuation

See full

Market cap$5.03B+533%

Returns & leverage

See full

Return on equity-27.3%-11.1pp

Debt / equity0×0.0×

Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s common stock, shares issued (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s common stock, shares issued (in shares)?: Oruka Therapeutics, Inc. (ORKA) reported common stock, shares issued (in shares) of $50.17M in Q1 2026.
How has Oruka Therapeutics, Inc.'s common stock, shares issued (in shares) changed year-over-year?: Oruka Therapeutics, Inc.'s common stock, shares issued (in shares) increased by 34.0% year-over-year, from $37.44M to $50.17M.